quinoxalines has been researched along with hby 097 in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (75.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, E; Hsiou, Y; Kirsch, R; Kleim, JP; Paessens, A; Riess, G; Rösner, M; Winkler, I | 1 |
| Bender, R; Kaiser, R; Kirsch, R; Kleim, JP; Meichsner, C; Paessens, A; Rösner, M; Rübsamen-Waigmann, H; Schneweis, KE; Wichers, M | 1 |
| Kirsch, R; Kleim, JP; Paessens, A; Riess, G; Rösner, M; Rübsamen-Waigmann, H; Winkler, I | 1 |
| Huguenel, E; Kleim, JP; Paessens, A; Rübsamen-Waigmann, H; Shah, A; Wainberg, MA | 1 |
| Balzarini, J; De Clercq, E; Kleim, JP; Pelemans, H; Riess, G; Roesner, M; Winkler, I | 2 |
| Agarwal, VK; Krol, GJ; Krone, V; Roberts, D | 1 |
| Arnold, E; Clark, AD; Das, K; Ding, J; Hsiou, Y; Hughes, SH; Kleim, JP; Riess, G; Rösner, M; Winkler, I | 1 |
| Balzarini, J; Dunkler, A; Kleim, JP; Merigan, TC; Oette, D; Riess, G; Suarez, JR; Winkler, I; Winters, M | 1 |
| Dietrich, U; Huguenel, E; Immelmann, A; Paessens, A; Rübsamen-Waigmann, H; Ruoff, HJ; Shah, A; von Briesen, H; Wainberg, MA | 1 |
| Aweeka, F; Hayashi, S; Jayesekera, D; Jayewardene, A; Shah, A; Thevanayagam, L | 1 |
| Balzarini, J; De Clercq, E; Desmyter, J; Esnouf, R; Kleim, JP; Pannecouque, C; Schmit, JC; Van Laethem, K; Van Remoortel, B; Vandamme, AM; Witvrouw, M | 1 |
| Pieribone, V | 1 |
| Arnold, E; Boyer, PL; Clark, AD; Das, K; Ding, J; Hsiou, Y; Hughes, SH; Janssen, PA; Kleim, JP; Lewi, P; Rösner, M | 1 |
| Arnold, E; Boyer, PL; Clark, AD; Das, K; Hughes, SH; Sarafianos, SG | 1 |
| Manallack, DT | 1 |
| Coluccia, A; La Regina, G; Silvestri, R | 1 |
1 review(s) available for quinoxalines and hby 097
| Article | Year |
|---|---|
Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Binding Sites; Cell Line; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Models, Molecular; Molecular Conformation; Nitriles; Phosphinic Acids; Pyrazoles; Pyridazines; Pyridines; Pyrimidines; Quinoxalines; Reverse Transcriptase Inhibitors; Rilpivirine | 2010 |
5 trial(s) available for quinoxalines and hby 097
| Article | Year |
|---|---|
Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiviral Agents; Cohort Studies; Double-Blind Method; Drug Combinations; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Mutation; Placebos; Quinoxalines; Reverse Transcriptase Inhibitors; Viral Load; Viremia; Virus Replication | 1997 |
Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Quinoxalines; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Zidovudine | 1999 |
Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Genotype; HIV Infections; HIV-1; Humans; Mutation; Phenotype; Quinoxalines; Reverse Transcriptase Inhibitors; Viral Load | 1999 |
Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients.
Topics: Adult; Antiviral Agents; Area Under Curve; Drug Interactions; Drug Therapy, Combination; Exanthema; Female; Gastrointestinal Diseases; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Middle Aged; Quinoxalines; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Los Angeles, New York, Stanford University: HBY 097, new drug may weaken HIV.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV; HIV Reverse Transcriptase; Humans; Los Angeles; Mutation; New York; Quinoxalines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; San Francisco | 1995 |
14 other study(ies) available for quinoxalines and hby 097
| Article | Year |
|---|---|
[New substance against AIDS in clinical trial].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials, Phase I as Topic; HIV Reverse Transcriptase; Humans; Quinoxalines; Reverse Transcriptase Inhibitors | 1995 |
Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Le
Topics: Antiviral Agents; Base Sequence; DNA Primers; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Molecular Sequence Data; Mutation; Quinoxalines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Selection, Genetic; Virus Replication | 1996 |
Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.
Topics: Animals; Antiviral Agents; Base Sequence; Dogs; Drug Resistance; Female; HIV-1; Humans; Mice; Molecular Sequence Data; Quinoxalines; Reverse Transcriptase Inhibitors; Virus Replication | 1995 |
In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097.
Topics: Antiviral Agents; Drug Resistance, Microbial; Genotype; HIV Reverse Transcriptase; Humans; Molecular Structure; Mutation; Phenotype; Quinoxalines; Reverse Transcriptase Inhibitors | 1997 |
Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine.
Topics: Anti-HIV Agents; Antiviral Agents; Cells, Cultured; Drug Resistance; HIV-1; Humans; Lamivudine; Mutation; Quinoxalines; Reverse Transcriptase Inhibitors; Zidovudine | 1997 |
Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined
Topics: Anti-HIV Agents; Antiviral Agents; Benzodiazepines; Cell Line; Delavirdine; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Lamivudine; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Nevirapine; Quinoxalines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Quantitative analysis of HBY 097 and its metabolites in human serum and urine by HPLC.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Humans; Models, Chemical; Quinoxalines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity | 1998 |
Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.
Topics: Antiviral Agents; Crystallography, X-Ray; Drug Design; Drug Resistance; Glutamic Acid; Glycine; HIV Reverse Transcriptase; Leucine; Models, Molecular; Molecular Conformation; Mutation; Quinoxalines; Reverse Transcriptase Inhibitors; Tyrosine | 1998 |
Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.
Topics: Anti-HIV Agents; Antiviral Agents; Binding Sites; Drug Resistance, Microbial; Drug Resistance, Multiple; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nucleosides; Phenotype; Quinoxalines; Reverse Transcriptase Inhibitors | 2001 |
Overcoming resistance to reverse transcriptase inhibitors.
Topics: Antiviral Agents; DNA, Viral; Drug Resistance, Microbial; HIV; Humans; Mutation; Quinoxalines; Reverse Transcriptase Inhibitors; RNA, Viral; Virus Replication | 1995 |
New type of HIV drug.
Topics: Antiviral Agents; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1; Quinoxalines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 1995 |
The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
Topics: Acetamides; Acetophenones; Amino Acid Substitution; Antiviral Agents; Binding Sites; Crystallography, X-Ray; Drug Design; Drug Resistance, Microbial; Enzyme Stability; HIV Reverse Transcriptase; HIV-1; Hydrogen Bonding; Ligands; Models, Molecular; Mutation, Missense; Protein Conformation; Protein Subunits; Quinoxalines; Reverse Transcriptase Inhibitors; Thermodynamics | 2001 |
Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
Topics: Adenosine Triphosphate; Amino Acid Substitution; Anti-HIV Agents; Binding Sites; Crystallography, X-Ray; DNA; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Manganese; Models, Molecular; Molecular Conformation; Mutation; Protein Conformation; Quinoxalines; Reverse Transcriptase Inhibitors | 2007 |
The use of local surface properties for molecular superimposition.
Topics: Amino Acid Chloromethyl Ketones; Anti-HIV Agents; Anticoagulants; Antimetabolites, Antineoplastic; Crystallography, X-Ray; Dipeptides; Folic Acid; HIV Protease Inhibitors; Humans; Imidazoles; Ligands; Methotrexate; Models, Molecular; Molecular Structure; Piperidines; Protein Binding; Proteins; Quinoxalines; Reverse Transcriptase Inhibitors; Software; Static Electricity; Structure-Activity Relationship; Sulfur Compounds; Surface Properties; Tetrahydrofolate Dehydrogenase | 2008 |